bemcentinib
Small moleculeexperimental
Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics. — Wikipedia
Clinical trial activity
8 trials · 19 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2018 (NCT03654833)
Timeline
Indications
Studied for
- Brain Neoplasms · Early Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- COVID-19 · Phase 2
- Glioblastoma · Phase 1
- Leukemia, Myeloid, Acute · Phase 2
- Lung Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1
- Mesothelioma, Malignant · Phase 2
- Myelodysplastic Syndromes · Phase 2
- Pancreatic Neoplasms · Phase 1/Phase 2
Mechanism of action
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2- Mol. weight
- 506.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBemcentinib ↗
- ChEMBLCHEMBL3809489 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06516887 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2024 | National Cancer Institute (NCI), University of Texas, San Antonio |
| NCT05469178 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2022 | BerGenBio ASA |
| NCT06469138 | Phase 1 | Aug 2, 2022 | BerGenBio ASA |
| NCT04890509 | Phase 2 | Oct 20, 2020 | BerGenBio ASA |
| NCT03965494 | Early Phase 1 (Phase 1) | Aug 1, 2019 | BerGenBio ASA, Johns Hopkins University, National Cancer Institute (NCI), University of Alabama, Birmingham |
| NCT03824080 | Phase 2 | Dec 20, 2018 | BerGenBio ASA, Free University of Amsterdam, Groupe Francophone des Myelodysplasies, GWT-TUD GmbH, Technical University of Dresden |
| NCT03649321 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2018 | BerGenBio ASA, TGen Drug Development, The University of Texas, Dallas, Triligent International |
| NCT03654833 | Phase 2 | Oct 1, 2018 | BerGenBio ASA, British Lung Foundation, Clovis Oncology, Eli Lilly, Merck, Roche, The Christie NHS Foundation Trust, University of Leicester |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (19)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BerGenBio ASA | For profit | 7 | 3 | 2 | 2018 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2019 |
| British Lung Foundation | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Clovis Oncology | For profit | 1 | 0 | 1 | 2018 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2018 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Groupe Francophone des Myelodysplasies | Academic/Hospital | 1 | 0 | 1 | 2018 |
| GWT-TUD GmbH | For profit | 1 | 1 | 1 | 2018 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Merck | For profit | 1 | 0 | 1 | 2018 |
| Roche | For profit | 1 | 0 | 1 | 2018 |
| Technical University of Dresden | Academic/Hospital | 1 | 0 | 1 | 2018 |
| TGen Drug Development | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The Christie NHS Foundation Trust | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Triligent International | For profit | 1 | 0 | 1 | 2018 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Leicester | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2024 |
19 organizations
Page 1 / 1